Substantial decreases in obsessive–compulsive symptoms during stimulation of the subthalamic nucleus in Parkinson disease have been previously reported. Mallet et al. hypothesized that the ...

Starting today, people with Parkinson’s disease will have a new treatment option, thanks to U.S. Food and Drug Administration approval of groundbreaking new technology.

The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.

The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...

The study, "The human subthalamic nucleus transiently inhibits active attentional processes," was published online March 4 in the journal Brain. The subthalamic nucleus is a pea-sized brain area ...